tiprankstipranks
Trending News
More News >
Xvivo Perfusion AB (SE:XVIVO)
:XVIVO

Xvivo Perfusion AB (XVIVO) Price & Analysis

Compare
2 Followers

XVIVO Stock Chart & Stats

kr192.70
-kr5.00(-1.20%)
At close: 4:00 PM EST
kr192.70
-kr5.00(-1.20%)

Bulls Say, Bears Say

Bulls Say
Strong Balance SheetLow leverage and sizable equity give XVIVO financial flexibility to fund R&D, commercial expansion or withstand cyclical softness. A stronger balance sheet supports durability through transplant adoption cycles and reduces refinancing risk over the next 2–6 months.
Recurring Consumables Revenue ModelA device-plus-consumables model creates recurring, per-procedure revenue and higher customer switching costs. This structural revenue stream supports predictable demand and margin resilience as clinical adoption grows across transplant centers over time.
Historic Revenue Growth & Healthy Gross MarginsSustained revenue expansion and healthy gross margins through 2024 indicate product-market fit and pricing power. These fundamentals mean that if demand normalizes, unit economics can restore profitability without requiring radical cost cuts.
Bears Say
2025 Revenue And Margin PullbackA sharp year-over-year decline in revenue and collapse in net margin signals structural demand, pricing, or cost issues. If persistent, lower scale and compressed margins will reduce reinvestment capacity and pressure long-term growth prospects.
Weak Cash Flow ConversionInconsistent OCF and repeated negative free cash flow restrict internally funded growth and increase reliance on external capital. Over a multi-month horizon, this limits capex, commercialization pace, and makes the company more vulnerable to execution setbacks.
Declining Return On EquityA fall to low-single-digit ROE reduces the company's ability to generate shareholder value from existing capital. Persistently low ROE can signal structural inefficiencies or margin pressure that hamper long-term investor support and strategic options.

Xvivo Perfusion AB News

XVIVO FAQ

What was Xvivo Perfusion AB’s price range in the past 12 months?
Xvivo Perfusion AB lowest stock price was kr160.00 and its highest was kr444.50 in the past 12 months.
    What is Xvivo Perfusion AB’s market cap?
    Xvivo Perfusion AB’s market cap is kr5.67B.
      When is Xvivo Perfusion AB’s upcoming earnings report date?
      Xvivo Perfusion AB’s upcoming earnings report date is Apr 24, 2026 which is in 52 days.
        How were Xvivo Perfusion AB’s earnings last quarter?
        Xvivo Perfusion AB released its earnings results on Jan 27, 2026. The company reported kr1.045 earnings per share for the quarter, beating the consensus estimate of kr0.684 by kr0.361.
          Is Xvivo Perfusion AB overvalued?
          According to Wall Street analysts Xvivo Perfusion AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Xvivo Perfusion AB pay dividends?
            Xvivo Perfusion AB does not currently pay dividends.
            What is Xvivo Perfusion AB’s EPS estimate?
            Xvivo Perfusion AB’s EPS estimate is 0.65.
              How many shares outstanding does Xvivo Perfusion AB have?
              Xvivo Perfusion AB has 31,499,470 shares outstanding.
                What happened to Xvivo Perfusion AB’s price movement after its last earnings report?
                Xvivo Perfusion AB reported an EPS of kr1.045 in its last earnings report, beating expectations of kr0.684. Following the earnings report the stock price went up 3.565%.
                  Which hedge fund is a major shareholder of Xvivo Perfusion AB?
                  Currently, no hedge funds are holding shares in SE:XVIVO
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Xvivo Perfusion AB

                    Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.

                    Xvivo Perfusion AB (XVIVO) Earnings & Revenues

                    XVIVO Company Deck

                    XVIVO Earnings Call

                    Q4 2026
                    0:00 / 0:00
                    Earnings Call Sentiment|Neutral
                    The earnings call highlighted significant growth in the Abdominal segment and strategic partnerships for service expansion in the U.S. However, challenges remain with slowed growth in the U.S. lung market and delays in regulatory approvals for heart and liver products.View all SE:XVIVO earnings summaries
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Getinge
                    Vitrolife AB
                    CellaVision AB
                    Paxman AB
                    Sedana Medical AB

                    Options Prices

                    Currently, No data available
                    ---
                    Popular Stocks